Skip to main content

Table 4 Most common AEs occurring in ≥20% of patients

From: Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

AE, n (%) Vemurafenib (N = 46)
  Any grade Grade ≥ 3
At least 1 AE 46 (100) 7 (15.2)
Dermatitis acneiform 30 (65.2) 0
Arthralgia 30 (65.2) 0
Blood cholesterol level increase 27 (58.7) 1 (2.2)
Diarrhea 27 (58.7) 0
Blood bilirubin level increase 25 (54.3) 0
Melanocytic nevus 24 (52.2) 0
Alopecia 23 (50.0) 0
Palmar-plantar erythrodysesthesia syndrome 22 (47.8) 0
Photosensitivity reaction 17 (37.0) 0
Fatigue 14 (30.4) 0
Pyrexia 13 (28.3) 0
Rash maculopapular 12 (26.1) 0
γ-glutamyltransferase level increase 11 (23.9) 1 (2.2)
Proteinuria 11 (23.9) 0
Total bile acid level increase 10 (21.7) 0
Hypertriglyceridemia 10 (21.7) 0
Leukopenia 10 (21.7) 0
  1. AE adverse event